These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 7847409)

  • 1. Adverse reactions related to i.v. infusion of high-dose cyclophosphamide in bone marrow transplant patients.
    Schwinghammer TL; Wiggins LE; Burgunder MR; Michell TE; Bailey WL
    Am J Hosp Pharm; 1994 Oct; 51(19):2419-21. PubMed ID: 7847409
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation.
    Abbott B; Ippoliti C; Bruton J; Neumann J; Whaley R; Champlin R
    Bone Marrow Transplant; 1999 Feb; 23(3):265-9. PubMed ID: 10084258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
    Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
    Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constant intravenous pentoxifylline infusions in allogeneic marrow transplant recipients: results of a dose escalation study.
    Beelen DW; Sayer HG; Franke M; Scheulen ME; Quabeck K; Mohnke M; Oidtmann M; Schaefer UW
    Bone Marrow Transplant; 1993 Oct; 12(4):363-70. PubMed ID: 8275036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
    Chen TL; Passos-Coelho JL; Noe DA; Kennedy MJ; Black KC; Colvin OM; Grochow LB
    Cancer Res; 1995 Feb; 55(4):810-6. PubMed ID: 7850794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unrelated donor bone marrow transplants for severe aplastic anemia with conditioning using total body irradiation and cyclophosphamide.
    Kim SY; Lee JW; Lim J; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Kim CC
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):863-70. PubMed ID: 17580265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
    Muus P; Donnelly P; Schattenberg A; Linssen P; Minderman H; Dompeling E; de Witte T
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):47-52. PubMed ID: 8290971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
    Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
    Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies.
    Bandini G; Belardinelli A; Rosti G; Calori E; Motta MR; Rizzi S; Benini C; Tura S
    Bone Marrow Transplant; 1994 May; 13(5):577-81. PubMed ID: 8054910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan.
    Kim SE; Lee JH; Choi SJ; Lee JH; Ryu SG; Lee KH
    Haematologica; 2005 Feb; 90(2):285-6. PubMed ID: 15710597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
    Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
    Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon.
    Gryn J; Johnson E; Goldman N; Devereux L; Grana G; Hageboutros A; Fernandez E; Constantinou C; Harrer W; Viner E; Goldberg J
    Bone Marrow Transplant; 1997 Feb; 19(3):221-6. PubMed ID: 9028549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation.
    McGuire DB; Altomonte V; Peterson DE; Wingard JR; Jones RJ; Grochow LB
    Oncol Nurs Forum; 1993; 20(10):1493-502. PubMed ID: 8278277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
    Jillella AP; Doria R; Khan K; Zelterman D; Ahmad YH; Smith BR; Holmes W; Becker P; Roberts KB; Rappeport JM
    Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary excretion and pharmacokinetics of acrolein and its parent drug cyclophosphamide in bone marrow transplant patients.
    Al-Rawithi S; El-Yazigi A; Ernst P; Al-Fiar F; Nicholls PJ
    Bone Marrow Transplant; 1998 Sep; 22(5):485-90. PubMed ID: 9733272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.
    Lee JH; Choi SJ; Lee JH; Kim SE; Park CJ; Chi HS; Lee MS; Lee JS; Kim WK; Lee KH
    Ann Hematol; 2005 May; 84(5):321-30. PubMed ID: 15580502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects.
    Thall PF; Champlin RE; Andersson BS
    Bone Marrow Transplant; 2004 Jun; 33(12):1191-9. PubMed ID: 15122310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
    Wu DP; Milpied N; Moreau P; Mechinaud-Lacroix F; Mahe B; Le Tortorec S; Rapp MJ; Bourdin S; Mahe JM; Harousseau JL
    Bone Marrow Transplant; 1994 Nov; 14(5):751-7. PubMed ID: 7889008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial.
    Stiff PJ; Bayer R; Tan S; Camarda M; Sosman J; Peace D; Kinch L; Rad N; Loutfi S
    Clin Cancer Res; 1995 Dec; 1(12):1495-502. PubMed ID: 9815949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.